Crispr Therapeutics AG vs M&T Bank Corporation — how do they compare? Crispr Therapeutics AG trades at $54.08 (market cap $5.23B), while M&T Bank Corporation trades at $251.93 (market cap $36.42B). The key difference: M&T Bank Corporation is far larger — about 7× Crispr Therapeutics AG's market cap, and M&T Bank Corporation pays a 2.38% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | MTB | |
|---|---|---|
Market Cap | $5.23B | $36.42B |
Sector | Health | Financials |
52-Week High | $76.78 | $254.04 |
52-Week Low | $44.34 | $178.63 |
Enterprise Value | $3.65B | — |
Dividend Yield | — | 2.38% |
Trailing returns across standard periods
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
Read more on MTB →